Table 4.
Weighted outcome means, outcome measures as estimated by random-effects models (for overall outcomes) or mixed-effects models (for treatment-group outcomes), and heterogeneity (I2) across studies.
| Variable | Number of eyes (studies included) | Weighted mean | Random or mixed-effects estimate (95% CI) | I2 (%) |
|---|---|---|---|---|
| Females, % | ||||
| Overall | 2378 (39) | 52.5 | 52.7 (49.6, 55.8) | 48.0 |
| Bevacizumab 1.25 mg | 1404 (23) | 54.2 | 54.8 (50.9, 58.8) | |
| Bevacizumab 2.5 mg | 167 (3) | 47.6 | 48.0 (37.3, 58.6) | |
| Dexamethasone | 226 (5) | 51.6 | 52.9 (44.1, 61.8) | |
| Ranibizumab | 384 (9) | 48.2 | 47.6 (40.8, 54.4) | |
| Triamcinolone | 197 (5) | 54.3 | 53.1 (44.3, 62.0) | |
| Baseline age | ||||
| Overall | 2267 (40) | 63.9 | 63.9 (62.3, 65.5) | 91.2 |
| Bevacizumab 1.25 mg | 1293 (24) | 64.2 | 63.4 (61.6, 65.3) | |
| Bevacizumab 2.5 mg | 167 (3) | 61.5 | 64.3 (60.7, 67.8) | |
| Dexamethasone | 226 (5) | 63.2 | 65.8 (62.9, 68.6) | |
| Ranibizumab | 384 (9) | 65.9 | 65.0 (62.1, 68.0) | |
| Triamcinolone | 197 (5) | 60.2 | 62.1 (59.2, 65.0) | |
| Baseline VA | ||||
| Overall | 2271 (40) | 52.8 | 54.0 (51.5, 56.5) | 91.2 |
| Bevacizumab 1.25 mg | 1293 (24) | 52.6 | 52.0 (49.4, 54.6) | |
| Bevacizumab 2.5 mg | 167 (3) | 47.4 | 50.2 (44.4, 56.1) | |
| Dexamethasone | 203 (5) | 50.8 | 53.6 (48.9, 58.3) | |
| Ranibizumab | 411 (10) | 61.2 | 61.6 (57.7, 65.5) | |
| Triamcinolone | 197 (5) | 43.8 | 49.4 (45.2, 53.6) | |
| ∆VA 6 months | ||||
| Overall | 1515 (26) | 13.0 | 12.4 (10.4, 14.5) | 68.2 |
| Bevacizumab 1.25 mg | 752 (14) | 13.6 | 13.1 (10.2, 15.9) | |
| Bevacizumab 2.5 mg | 133 (2) | 17.4 | 14.4 (6.8, 22.0) | |
| Dexamethasone | 134 (3) | 12.0 | 11.8 (5.5, 18.2) | |
| Ranibizumab | 299 (8) | 10.7 | 12.8 (8.4, 17.1) | |
| Triamcinolone | 197 (5) | 12.2 | 8.8 (3.3, 14.3) | |
| ∆VA 1 year | ||||
| Overall | 1727 (29) | 14.1 | 14.6 (12.5, 16.7) | 77.5 |
| Bevacizumab 1.25 mg | 1049 (20) | 14.5 | 15.5 (13.4, 17.6) | |
| Bevacizumab 2.5 mg | 133 (2) | 20.8 | 18.3 (11.1, 25.5) | |
| Dexamethasone | 128 (3) | 9.1 | 10.9 (5.5, 16.2) | |
| Ranibizumab | 273 (7) | 11.8 | 15.9 (11.3, 20.5) | |
| Triamcinolone | 144 (3) | 14.1 | 10.8 (4.5, 17.1) | |
| ∆VA 2 years | ||||
| Overall | 491 (7) | 14.0 | 13.2 (7.9, 18.6) | 64.2 |
| Bevacizumab 1.25 mg | 211 (4) | 13.4 | 10.9 (−29.6, 51.4) | |
| Bevacizumab 2.5 mg | 133 (2) | 20.0 | 16.1 (−39.1, 71.3) | |
| Dexamethasone | 41 (1) | 3.0 | – | |
| Ranibizumab | 75 (2) | 9.9 | 12.4 (−39.0, 63.8) | |
| Triamcinolone | 31 (1) | 17.5 | – | |
| Baseline CST | ||||
| Overall | 2199 (40) | 503.8 | 501.3 (483.5, 519.1) | 86.3 |
| Bevacizumab 1.25 mg | 1293 (24) | 497.9 | 491.9 (469.6, 514.2) | |
| Bevacizumab 2.5 mg | 72 (2) | 518.6 | 507.1 (440.1, 574.1) | |
| Dexamethasone | 257 (6) | 500.1 | 523.5 (489.3, 557.6) | |
| Ranibizumab | 411 (10) | 528.6 | 508.3 (474.9, 541.7) | |
| Triamcinolone | 166 (4) | 488.5 | 514.3 (471.6, 557.0) | |
| Overall | 1294 (25) | −167.2 | −159.2 (−203.8, −114.6) | 93.9 |
| Bevacizumab 1.25 mg | 662 (13) | −185.4 | −186.2 (−240.0, −132.5) | |
| Bevacizumab 2.5 mg | 38 (1) | −198.0 | – | |
| Dexamethasone | 216 (5) | −154.8 | −101.8 (−162.5, −41.1) | |
| Ranibizumab | 299 (8) | −141.9 | −161.0 (−242.6, −79.5) | |
| Triamcinolone | 79 (3) | −129.0 | −159.4 (−249.6, −69.2) | |
| ∆CST 1 year | ||||
| Overall | 1325 (24) | −190.8 | −181.7 (−230.7, −132.7) | 96.1 |
| Bevacizumab 1.25 mg | 829 (17) | −206.6 | −198.2 (−250.6, −145.9) | |
| Bevacizumab 2.5 mg | 38 (1) | −194.0 | – | |
| Dexamethasone | 128 (3) | −184.3 | −143.1 (−213.2, −73.0) | |
| Ranibizumab | 242 (6) | −128.8 | −189.8 (−296.9, −82.6) | |
| Triamcinolone | 88 (2) | −221.3 | −189.2 (−266.9, −111.6) | |
| ∆CST 2 years | ||||
| Overall | 303 (5) | −236.3 | −209.3 (−328.1, −90.6) | 93.6 |
| Bevacizumab 1.25 mg | 149 (3) | −262.9 | −213.2 (−501.9, 75.5) | |
| Bevacizumab 2.5 mg | 38 (1) | −210.0 | – | |
| Dexamethasone | 41 (1) | −256.0 | – | |
| Ranibizumab | 75 (2) | −186.0 | −184.0 (−539.3, 171.3) | |
| Triamcinolone | – | – | – | |
| Injections 6 months | ||||
| Overall | 692 (10) | 2.5 | 2.7 (1.9, 3.4) | 98.1 |
| Bevacizumab 1.25 mg | 579 (7) | 2.6 | 2.9 (2.1, 3.6) | |
| Bevacizumab 2.5 mg | – | – | – | |
| Dexamethasone | 31 (1) | 1.1 | – | |
| Ranibizumab | 54 (2) | 3.3 | 3.3 (2.1, 4.5) | |
| Triamcinolone | 28 (1) | 1.0 | – | |
| Injections 12 months | ||||
| Overall | 1337 (24) | 3.5 | 3.6 (2.9, 4.2) | 99.6 |
| Bevacizumab 1.25 mg | 882 (17) | 3.7 | 3.4 (2.8, 4.0) | |
| Bevacizumab 2.5 mg | – | – | – | |
| Dexamethasone | 69 (2) | 1.8 | 2.1 (1.4, 2.8) | |
| Ranibizumab | 273 (7) | 4.2 | 4.9 (4.2, 5.6) | |
| Triamcinolone | 113 (2) | 1.2 | 2.0 (1.3, 2.7) | |
| Injections 24 months | ||||
| Overall | 365 (6) | 5.0 | 5.2 (2.1, 8.3) | 98.2 |
| Bevacizumab 1.25 mg | 211 (4) | 5.3 | 5.7 (0.0, 15.3) | |
| Bevacizumab 2.5 mg | 38 (1) | 4.3 | – | |
| Dexamethasone | 41 (1) | 2.7 | – | |
| Ranibizumab | 75 (2) | 5.7 | 5.6 (0.0, 21.9) | |
| Triamcinolone | – | – | – | |
Dashes indicate no studies (or only 1 for random- and mixed-effects estimates) were available for that treatment group. Moderators for mixed-effects estimates analysing outcomes by treatment group included age, VA and CST measured at baseline.